Collegium Pharmaceutical Stock Forecast, Price & News

+0.12 (+0.61 %)
(As of 09/21/2021 03:51 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume11,170 shs
Average Volume391,195 shs
Market Capitalization$702.39 million
P/E Ratio7.26
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive COLL News and Ratings via Email

Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Collegium Pharmaceutical logo

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The firm engages in the development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.42 out of 5 stars

Medical Sector

167th out of 1,352 stocks

Pharmaceutical Preparations Industry

76th out of 665 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 4.4 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Collegium Pharmaceutical (NASDAQ:COLL) Frequently Asked Questions

Is Collegium Pharmaceutical a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Collegium Pharmaceutical stock.
View analyst ratings for Collegium Pharmaceutical
or view top-rated stocks.

What stocks does MarketBeat like better than Collegium Pharmaceutical?

Wall Street analysts have given Collegium Pharmaceutical a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Collegium Pharmaceutical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Collegium Pharmaceutical?

Collegium Pharmaceutical saw a drop in short interest during the month of August. As of August 13th, there was short interest totaling 3,620,000 shares, a drop of 12.1% from the July 29th total of 4,120,000 shares. Based on an average daily trading volume, of 305,200 shares, the short-interest ratio is currently 11.9 days. Approximately 10.5% of the company's stock are sold short.
View Collegium Pharmaceutical's Short Interest

When is Collegium Pharmaceutical's next earnings date?

Collegium Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Collegium Pharmaceutical

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) announced its earnings results on Thursday, August, 5th. The specialty pharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.34 by $0.07. The specialty pharmaceutical company earned $82.94 million during the quarter, compared to the consensus estimate of $84.29 million. Collegium Pharmaceutical had a net margin of 32.73% and a trailing twelve-month return on equity of 22.59%.
View Collegium Pharmaceutical's earnings history

How has Collegium Pharmaceutical's stock been impacted by Coronavirus (COVID-19)?

Collegium Pharmaceutical's stock was trading at $17.57 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, COLL shares have increased by 13.7% and is now trading at $19.97.
View which stocks have been most impacted by COVID-19

What guidance has Collegium Pharmaceutical issued on next quarter's earnings?

Collegium Pharmaceutical updated its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $335 million-$355 million, compared to the consensus revenue estimate of $346.30 million.

What price target have analysts set for COLL?

3 brokers have issued 12 month target prices for Collegium Pharmaceutical's stock. Their forecasts range from $22.00 to $32.00. On average, they expect Collegium Pharmaceutical's stock price to reach $27.33 in the next year. This suggests a possible upside of 36.9% from the stock's current price.
View analysts' price targets for Collegium Pharmaceutical
or view top-rated stocks among Wall Street analysts.

Who are Collegium Pharmaceutical's key executives?

Collegium Pharmaceutical's management team includes the following people:
  • Joseph J. Ciaffoni, President, Chief Executive Officer & Director
  • Colleen Tupper, Chief Financial Officer & Executive Vice President
  • Alison B. Fleming, Chief Technology Officer
  • Richard Malamut, Chief Medical Officer
  • Scott Dreyer, Chief Commercial Officer & Executive VP

What is Joseph Ciaffoni's approval rating as Collegium Pharmaceutical's CEO?

6 employees have rated Collegium Pharmaceutical CEO Joseph Ciaffoni on Joseph Ciaffoni has an approval rating of 68% among Collegium Pharmaceutical's employees.

Who are some of Collegium Pharmaceutical's key competitors?

What other stocks do shareholders of Collegium Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), (CGC), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH).

When did Collegium Pharmaceutical IPO?

(COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Who are Collegium Pharmaceutical's major shareholders?

Collegium Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.08%), Vanguard Group Inc. (6.30%), Renaissance Technologies LLC (3.51%), State Street Corp (3.25%), Principal Financial Group Inc. (2.93%) and Invesco Ltd. (2.74%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer and Shirley R Kuhlmann.
View institutional ownership trends for Collegium Pharmaceutical

Which major investors are selling Collegium Pharmaceutical stock?

COLL stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Rice Hall James & Associates LLC, Citadel Advisors LLC, Bank of New York Mellon Corp, JPMorgan Chase & Co., Legal & General Group Plc, Bank of America Corp DE, and Susquehanna International Group LLP. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include Alison B Fleming, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer, and Shirley R Kuhlmann.
View insider buying and selling activity for Collegium Pharmaceutical
or view top insider-selling stocks.

Which major investors are buying Collegium Pharmaceutical stock?

COLL stock was purchased by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., Dimensional Fund Advisors LP, Massachusetts Financial Services Co. MA, Federated Hermes Inc., Charles Schwab Investment Management Inc., Millennium Management LLC, State Street Corp, and Vanguard Group Inc..
View insider buying and selling activity for Collegium Pharmaceutical
or or view top insider-buying stocks.

How do I buy shares of Collegium Pharmaceutical?

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Collegium Pharmaceutical's stock price today?

One share of COLL stock can currently be purchased for approximately $19.97.

How much money does Collegium Pharmaceutical make?

Collegium Pharmaceutical has a market capitalization of $710.21 million and generates $310.02 million in revenue each year. The specialty pharmaceutical company earns $26.75 million in net income (profit) each year or $0.76 on an earnings per share basis.

How many employees does Collegium Pharmaceutical have?

Collegium Pharmaceutical employs 234 workers across the globe.

What is Collegium Pharmaceutical's official website?

The official website for Collegium Pharmaceutical is

Where are Collegium Pharmaceutical's headquarters?

Collegium Pharmaceutical is headquartered at 100 Technology Center Drive, Stoughton MA, 02072.

How can I contact Collegium Pharmaceutical?

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at (781) 713-3699.

This page was last updated on 9/21/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.